Schwind showcases new excimer laser

Article

Three years of research and development paid off today when Schwind eye-tech-solutions unveiled the Schwind AMARIS excimer laser to the refractive surgery community. According to CEO Rolf Schwind, it successfully combines all available state-of-the-art technologies in one single system.

Three years of research and development paid off today when Schwind eye-tech-solutions unveiled the Schwind AMARIS excimer laser to the refractive surgery community. According to CEO Rolf Schwind, it successfully combines all available state-of-the-art technologies in one single system.

Boasting a 1,050 Hz turbo eye tracker (5 D eye tracker), with a response time of less than three milliseconds, and other features, such as rotation balance, limbus tracking and static as well as dynamic cylcotorsion control, the company believes that it has produced the fastest and most accurate eye tracking system on the market.

Accuracy of ablation is governed by the system's "TotalTech Laser", which has a true pulse frequency of 500 Hz and two automatically adapted fluence values. Depending on the refraction to be corrected, approximately 80% of the corneal ablation is performed with a high fluence (high-speed) level, whilst fine correction takes place with a low fluence level. According to Schwind, one diopter of correction takes on average less than 2.5 seconds with the Schwind AMARIS, whilst the small beam diameter of 0.54 mm (FWHM) allows maximum precision and smooth treatment surfaces.

The laser's Intelligent Thermal Effect Control has been designed to provide dynamically adapted distribution of the laser pulses, thus reducing significant heating of the cornea and offering maximum protection to the stroma.

Other valuable features highlighted by the firm include: the continuous measurement of corneal thickness (using online pachymetry) during the procedure; the particle aspiration system, which removes energy-reducing particles; the Treatment Assistant Manager (TAM), which guides the surgeon through each treatment step; and the unique ergonomics, which optimise the treatment process and contribute to patient comfort.

"With the Schwind AMARIS, we have developed an all-rounder with unmatched high performance, thereby offering an extraordinarily high level of accuracy and safety and the first and only laser to combine all state-of-the-art technologies in one system," enthused Rolf Schwind.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.